{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T18:14:43Z","timestamp":1649182483059},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,3,29]],"date-time":"2012-03-29T00:00:00Z","timestamp":1332979200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/2191-1991-2-3","type":"journal-article","created":{"date-parts":[[2012,3,29]],"date-time":"2012-03-29T06:14:03Z","timestamp":1333001643000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone\u00ae) in Spain"],"prefix":"10.1186","volume":"2","author":[{"given":"Jose","family":"Martinez-Raga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Gonzalez-Saiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"O\u00f1ate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itziar","family":"Oyag\u00fcez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliazar","family":"Sabater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,29]]},"reference":[{"key":"23_CR1","unstructured":"United Nations Office on Drugs and Crime: UNODC. World Drug Report 2010 (United Nations Publication, Sales No. E.10.XI.13)\n[http:\/\/www.unodc.org\/documents\/wdr\/WDR_2010\/World_Drug_Report_2010_lo-res.pdf]"},{"key":"23_CR2","unstructured":"Ministerio de Sanidad, Politica Social e Igualdad: National Program on Drugs (Plan Nacional sobre drogas) Observatorio Espa\u00f1ol sobre Drogas. Informe 2009\n[http:\/\/www.pnsd.mspsi.es\/Categoria2\/observa\/pdf\/oed-2009.pdf]"},{"key":"23_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0376-8716(00)00162-9","volume":"61","author":"TL Mark","year":"2001","unstructured":"Mark TL, Woody GE, Juday T, Kleber HD: The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001, 61: 195\u2013206. 10.1016\/S0376-8716(00)00162-9","journal-title":"Drug Alcohol Depend"},{"key":"23_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0376-8716(98)00044-1","volume":"52","author":"W Hall","year":"1998","unstructured":"Hall W, Darke S: Trends in opiate overdose deaths in Australia 1979\u20131995. Drug Alcohol Depend 1998, 52: 71\u201377. 10.1016\/S0376-8716(98)00044-1","journal-title":"Drug Alcohol Depend"},{"key":"23_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1517\/14656566.5.4.713","volume":"5","author":"G Gonzalez","year":"2004","unstructured":"Gonzalez G, Oliveto A, Kosten TR: Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother 2004, 5: 713\u2013725. 10.1517\/14656566.5.4.713","journal-title":"Expert Opin Pharmacother"},{"key":"23_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cpr.2009.10.006","volume":"30","author":"JC Veilleux","year":"2010","unstructured":"Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ: A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 2010, 30: 155\u2013166. 10.1016\/j.cpr.2009.10.006","journal-title":"Clin Psychol Rev"},{"key":"23_CR7","doi-asserted-by":"crossref","unstructured":"Gowing L, Farrell M, Ali R, White JM: Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2009, (2):CD002024.","DOI":"10.1002\/14651858.CD002024.pub3"},{"key":"23_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3109\/15622975.2011.561872","volume":"12","author":"M Soyka","year":"2011","unstructured":"Soyka M, Kranzler HR, van den Brink W, Krystal J, M\u00f6ller HJ, Kasper S, WFSBP Task Force on Treatment, Guidelines for Substance Use Disorders: The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. World J Biol Psychiatry 2011, 12: 160\u2013187. 10.3109\/15622975.2011.561872","journal-title":"World J Biol Psychiatry"},{"key":"23_CR9","first-page":"33","volume":"66","author":"A Uchtenhagen","year":"2003","unstructured":"Uchtenhagen A: Substitution management in opioid dependence. J Neural Transm Suppl 2003, 66: 33\u201360.","journal-title":"J Neural Transm Suppl"},{"key":"23_CR10","doi-asserted-by":"publisher","first-page":"594","DOI":"10.12968\/hmed.2007.68.11.27681","volume":"68","author":"S George","year":"2007","unstructured":"George S, Day E: Buprenorphine in the treatment of opioid dependence. Br J Hosp Med (Lond) 2007, 68: 594\u2013597.","journal-title":"Br J Hosp Med (Lond)"},{"key":"23_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1521-0391.2010.00086.x","volume":"19","author":"I Maremmani","year":"2010","unstructured":"Maremmani I, Gerra G: Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment. Am J Addict 2010, 19: 557\u2013568. 10.1111\/j.1521-0391.2010.00086.x","journal-title":"Am J Addict"},{"key":"23_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.drugalcdep.2003.11.017","volume":"75","author":"G Gerra","year":"2004","unstructured":"Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, Bertacca S: Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 2004, 75: 37\u201345. 10.1016\/j.drugalcdep.2003.11.017","journal-title":"Drug Alcohol Depend"},{"key":"23_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/02791072.1994.10472259","volume":"26","author":"W Ling","year":"1994","unstructured":"Ling W, Rawson RA, Compton MA: Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J Psychoactive Drugs 1994, 26: 119\u2013128. 10.1080\/02791072.1994.10472259","journal-title":"J Psychoactive Drugs"},{"key":"23_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","volume":"93","author":"W Ling","year":"1998","unstructured":"Ling W, Charuvastra C, Collins JF, Batki S, Brown LS Jr, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA Jr, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D: Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998, 93: 475\u2013486. 10.1046\/j.1360-0443.1998.9344753.x","journal-title":"Addiction"},{"key":"23_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0376-8716(95)01186-2","volume":"40","author":"RE Johnson","year":"1995","unstructured":"Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE: A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995, 40: 17\u201325. 10.1016\/0376-8716(95)01186-2","journal-title":"Drug Alcohol Depend"},{"key":"23_CR16","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","volume":"361","author":"J Kakko","year":"2003","unstructured":"Kakko J, Svanborg KD, Kreek MJ, Heilig M: 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003, 361: 662\u2013668. 10.1016\/S0140-6736(03)12600-1","journal-title":"Lancet"},{"key":"23_CR17","unstructured":"European Medicines Agency: Summary of Products Characteristics (Suboxone).\n[http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000697\/WC500058505.pdf]"},{"issue":"2 Suppl","key":"23_CR18","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","volume":"70","author":"RE Johnson","year":"2003","unstructured":"Johnson RE, Strain EC, Amass L: Buprenorphine: how to use it right. Drug Alcohol Depend 2003,70(2 Suppl):S59\u201377.","journal-title":"Drug Alcohol Depend"},{"key":"23_CR19","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa022164","volume":"349","author":"PJ Fudala","year":"2003","unstructured":"Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D: Buprenorphine\/Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphinenaloxone. N Engl J Med 2003, 349: 949\u2013958. 10.1056\/NEJMoa022164","journal-title":"N Engl J Med"},{"key":"23_CR20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1586\/14737167.5.5.583","volume":"5","author":"CM Doran","year":"2005","unstructured":"Doran CM: Buprenorphine, buprenorphine\/naloxone and methadone maintenance: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 2005, 5: 583\u2013591. 10.1586\/14737167.5.5.583","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"23_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000141641","volume":"14","author":"MJ Horspool","year":"2008","unstructured":"Horspool MJ, Seivewright N, Armitage CJ, Mathers N: Post-treatment outcomes of buprenorphine detoxification in community settings: a systematic review. Eur Addict Res 2008, 14: 179\u2013185. 10.1159\/000141641","journal-title":"Eur Addict Res"},{"issue":"Suppl 1","key":"23_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/11536010-000000000-00000","volume":"30","author":"F Magnelli","year":"2010","unstructured":"Magnelli F, Biondi L, Calabria R, Fiore A, Peluso E, Vonella D, Rota AG: Safety and efficacy of buprenorphine\/naloxone in opioid-dependent patients: an Italian observational study. Clin Drug Investig 2010,30(Suppl 1):21\u201326.","journal-title":"Clin Drug Investig"},{"key":"23_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1017\/S0266462309090072","volume":"25","author":"MG Niezen","year":"2009","unstructured":"Niezen MG, de Bont A, Busschbach JJ, Cohen JP, Stolk EA: Finding legitimacy for the role of budget impact in drug reimbursement decisions. Int J Technol Assess Health Care 2009, 25: 49\u201355. 10.1017\/S0266462309090072","journal-title":"Int J Technol Assess Health Care"},{"key":"23_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000259614","volume":"16","author":"J Mart\u00ednez-Raga","year":"2010","unstructured":"Mart\u00ednez-Raga J, Gonz\u00e1lez Saiz F, Pascual C, Casado MA, Sabater Torres FJ: Suboxone (buprenorphine\/naloxone) as an agonist opioid treatment in Spain: a budgetary impact analysis. Eur Addict Res 2010, 16: 31\u201342. 10.1159\/000259614","journal-title":"Eur Addict Res"},{"key":"23_CR25","first-page":"64","volume":"2","author":"M Brosa","year":"2005","unstructured":"Brosa M, Gisbert R, Rodr\u00edguez JM, Soto J: Principios, m\u00e9todos y aplicaciones del an\u00e1lisis del impacto presupuestario en el sector sanitario. PharmacoEconomics Span Res Art 2005, 2: 64\u201378.","journal-title":"PharmacoEconomics Span Res Art"},{"key":"23_CR26","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","volume":"10","author":"JA Mauskopf","year":"2007","unstructured":"Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P: Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health 2007, 10: 336\u2013347. 10.1111\/j.1524-4733.2007.00187.x","journal-title":"Value Health"},{"key":"23_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1524-4733.2004.71257.x","volume":"7","author":"E Orlewska","year":"2004","unstructured":"Orlewska E, Mierzejewski P: Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health 2004, 7: 1\u201310. 10.1111\/j.1524-4733.2004.71257.x","journal-title":"Value Health"},{"key":"23_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2165\/00019053-200119060-00001","volume":"19","author":"P Trueman","year":"2001","unstructured":"Trueman P, Drummond M, Hutton J: Developing guidance for budget impact analysis. Pharmacoeconomics 2001, 19: 855\u2013867. 10.2165\/00019053-200119080-00007","journal-title":"Pharmacoeconomics"},{"key":"23_CR29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/135581969800300307","volume":"3","author":"R Lilford","year":"1998","unstructured":"Lilford R, Royston G: Decision analysis in the selection, design and application of clinical and health services research. J Health Serv Res Policy 1998, 3: 159\u2013166.","journal-title":"J Health Serv Res Policy"},{"key":"23_CR30","unstructured":"Ministerio de Sanidad, Pol\u00edtica Social e Igualdad: National Program on Drugs (Plan Nacional sobre drogas) Memoria 2009\n[http:\/\/www.pnsd.msc.es\/Categoria2\/publica\/pdf\/memo2009.pdf]"},{"key":"23_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.drugalcdep.2007.06.013","volume":"91","author":"MA Sullivan","year":"2007","unstructured":"Sullivan MA, Garawi F, Bisaga A, Comer SD, Carpenter K, Raby WN, Anen SJ, Brooks AC, Jiang H, Akerele E, Nunes EV: Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend 2007, 91: 289\u2013292. 10.1016\/j.drugalcdep.2007.06.013","journal-title":"Drug Alcohol Depend"},{"key":"23_CR32","first-page":"CD001333","volume":"4","author":"S Minozzi","year":"2011","unstructured":"Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A: Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011, 4: CD001333.","journal-title":"Cochrane Database Syst Rev"},{"key":"23_CR33","unstructured":"World Health Organization: Collaboration centre for drugs statistics methodology.\n[http:\/\/www.whocc.no\/atc_ddd_index\/?code=N07BC51]"},{"key":"23_CR34","unstructured":"National Statistics Institute: Instituto Nacional de Estad\u00edstica. Indice de precios al consumo.\n[http:\/\/www.ine.es\/calcula\/index.do?L=0]"},{"key":"23_CR35","unstructured":"Royal Decree-Law [Real Decreto-ley 8\/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico. BOE de 24 de mayo de 2010:126]\n[http:\/\/www.boe.es\/boe\/dias\/2010\/05\/24\/pdfs\/BOE-A-2010\u20138228.pdf]"},{"key":"23_CR36","unstructured":"IMS Health. MIDAS, MAT. [database] 2010."},{"key":"23_CR37","first-page":"182","volume":"22","author":"JA Sacristan","year":"1998","unstructured":"Sacristan JA, Galende I, Soto J: Estudios natural\u00edsticos para valorar la efectividad de los medicamentos tras su comercializaci\u00f3n: \u00bfpor qu\u00e9, cu\u00e1ndo y c\u00f3mo? Aten Primaria 1998, 22: 182\u2013185.","journal-title":"Aten Primaria"},{"key":"23_CR38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1360-0443.2005.01039.x","volume":"100","author":"CJ de Wet","year":"2005","unstructured":"de Wet CJ, Reed LJ, Bearn J: The rise of buprenorphine prescribing in England: analysis of NHS regional data, 2001\u201303. Addiction 2005, 100: 495\u2013499. 10.1111\/j.1360-0443.2005.01039.x","journal-title":"Addiction"},{"key":"23_CR39","volume-title":"Qual Life Res","author":"DW Raisch","year":"2011","unstructured":"Raisch DW, Campbell HM, Garnand DA, Jones MA, Sather MR, Naik R, Ling W: Health-related quality of life changes associated with buprenorphine treatment for opioid dependence. Qual Life Res 2011, in press."},{"key":"23_CR40","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1370\/afm.665","volume":"5","author":"IL Mintzer","year":"2007","unstructured":"Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S: Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007, 5: 146\u2013150. 10.1370\/afm.665","journal-title":"Ann Fam Med"},{"key":"23_CR41","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/archpsyc.1996.01830050035005","volume":"53","author":"W Ling","year":"1996","unstructured":"Ling W, Wesson DR, Charuvastra C, Klett CJ: A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996, 53: 401\u2013407. 10.1001\/archpsyc.1996.01830050035005","journal-title":"Arch Gen Psychiatry"},{"key":"23_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0376-8716(00)00163-0","volume":"62","author":"S Petitjean","year":"2001","unstructured":"Petitjean S, Stohler R, D\u00e9glon JJ, Livoti S, Waldvogel D, Uehlinger C, Ladewig D: Double-blind randomized trial of buprenorphine and methadone in opiatedependence. Drug Alcohol Depend 2001, 62: 97\u2013104. 10.1016\/S0376-8716(00)00163-0","journal-title":"Drug Alcohol Depend"},{"key":"23_CR43","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","volume":"267","author":"RE Johnson","year":"1992","unstructured":"Johnson RE, Jaffe JH, Fudala PJ: A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992, 267: 2750\u20132755. 10.1001\/jama.1992.03480200058024","journal-title":"JAMA"},{"key":"23_CR44","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/ADM.0b013e3182312983","volume":"5","author":"ML Kraus","year":"2011","unstructured":"Kraus ML, Alford DP, Kotz MM, Levounis P, Mandell TW, Meyer M, Salsitz EA, Wetterau N, Wyatt SA: Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. J Addict Med 2011, 5: 254\u2013263. 10.1097\/ADM.0b013e3182312983","journal-title":"J Addict Med"},{"key":"23_CR45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0376-8716(00)00214-3","volume":"63","author":"R Rosenheck","year":"2001","unstructured":"Rosenheck R, Kosten T: Buprenorphine for opiate addiction: potential economic impact. Drug Alcohol Depend 2001, 63: 253\u2013262. 10.1016\/S0376-8716(00)00214-3","journal-title":"Drug Alcohol Depend"},{"key":"23_CR46","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0924-977X(03)00146-9","volume":"14","author":"E Davids","year":"2004","unstructured":"Davids E, Gastpar M: Buprenorphine in the treatment of opioid dependence. Eur Neuropsychopharmacol 2004, 14: 209\u2013216. 10.1016\/S0924-977X(03)00146-9","journal-title":"Eur Neuropsychopharmacol"},{"key":"23_CR47","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/hec.1603","volume":"20","author":"PP Barros","year":"2011","unstructured":"Barros PP: The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry. Health Econ 2011, 20: 461\u2013470. 10.1002\/hec.1603","journal-title":"Health Econ"},{"key":"23_CR48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.gaceta.2010.07.011","volume":"24","author":"J Esp\u00edn","year":"2010","unstructured":"Esp\u00edn J, Oliva J, Rodr\u00edguez-Barrios JM: Innovative patient access schemes for the adoption of new technology: risk-sharing agreements. Gac Sanit 2010, 24: 491\u2013497. 10.1016\/j.gaceta.2010.07.011","journal-title":"Gac Sanit"},{"key":"23_CR49","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10198-006-0386-6","volume":"7","author":"G de Pouvourville","year":"2006","unstructured":"de Pouvourville G: Risk-sharing agreements for innovative drugs: a new solution to old problems? Eur J Health Econ 2006, 7: 155\u2013157. 10.1007\/s10198-006-0386-6","journal-title":"Eur J Health Econ"},{"key":"23_CR50","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1017\/S1744133111000016","volume":"6","author":"F Antonanzas","year":"2011","unstructured":"Antonanzas F, Juarez-Castello C, Rodriguez-Ibeas R: Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Econ Policy Law 2011, 6: 391\u2013403. 10.1017\/S1744133111000016","journal-title":"Health Econ Policy Law"},{"key":"23_CR51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1472-6963-10-153","volume":"10","author":"J Adamski","year":"2010","unstructured":"Adamski J, Godman B, Ofierska-Sujkowska G, Osi\u0144ska B, Herholz H, Wendykowska K, Laius O, Jan S, Sermet C, Zara C, Kalaba M, Gustafsson R, Garuolien\u00e8 K, Haycox A, Garattini S, Gustafsson LL: Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 2010, 10: 153. 10.1186\/1472-6963-10-153","journal-title":"BMC Health Serv Res"}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2191-1991-2-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2191-1991-2-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/2191-1991-2-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T18:59:30Z","timestamp":1630522770000},"score":1,"resource":{"primary":{"URL":"https:\/\/healtheconomicsreview.biomedcentral.com\/articles\/10.1186\/2191-1991-2-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,29]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1186\/2191-1991-2-3","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,29]]},"assertion":[{"value":"10 January 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"3"}}